Carboplatin, Pemetrexed, and Sunitinib combination therapy

This is a combination therapy that has been studied in clinical trials, particularly for advanced solid malignancies. The combination consists of three distinct drugs: 1. **Carboplatin**: An alkylating agent and platinum-based chemotherapy drug 2. **Pemetrexed**: An antifolate chemotherapy drug (brand name Alimta) 3. **Sunitinib**: A tyrosine kinase inhibitor (brand name Sutent) ## Clinical Development The combination was investigated in a phase I dose-escalation study to determine the maximum tolerated dose (MTD) and overall safety in patients with advanced solid malignancies[1][2]. The study explored two different dosing schedules for sunitinib: 1. Continuous daily dosing (CDD) schedule 2. Schedule 2/1 (2 weeks on treatment followed by 1 week off treatment) The MTD on Schedule 2/1 was established as sunitinib 37.5 mg/day with pemetrexed 500 mg/m² and carboplatin AUC = 5 mg·min/ml[2]. The MTD on the CDD schedule was not established in the reported studies. ## Safety Profile The most common adverse events observed with this combination included: - **Hematologic toxicities**: Grade 3/4 neutropenia (83%), leukopenia (83%), and thrombocytopenia - **Non-hematologic toxicities**: Fatigue/asthenia, diarrhea, hand-foot syndrome, and anorexia[2] Dose-limiting toxicities included grade 3/4 neutropenia, grade 3 thrombocytopenia, and grade 3 hand-foot syndrome[2]. ## Pharmacokinetics Pharmacokinetic studies revealed no clinically significant drug-drug interactions between the components of this combination therapy[2][6]. Each drug maintains its characteristic pharmacokinetic profile: - **Sunitinib**: Slow absorption and elimination with a long half-life - **Pemetrexed**: Rapid elimination with a mean half-life of approximately 2.75 hours - **Carboplatin**: Standard platinum-based chemotherapy pharmacokinetics ## Efficacy In the phase I study, the best response at the Schedule 2/1 MTD was stable disease ≥8 weeks in 3/5 evaluable patients (60%)[2]. The combination was primarily investigated for potential use in non-small cell lung cancer (NSCLC) and mesothelioma, though it was studied in various advanced solid malignancies. ## Mechanism of Action This combination brings together three distinct mechanisms: 1. **Carboplatin**: Forms DNA crosslinks, inhibiting DNA replication and transcription 2. **Pemetrexed**: Inhibits multiple folate-dependent enzymes involved in DNA synthesis 3. **Sunitinib**: Inhibits multiple receptor tyrosine kinases (RTKs) involved in tumor growth and angiogenesis, including PDGFR, VEGFR, KIT, FLT3, CSF-1R, and RET[8] The rationale for combining these agents likely stems from their complementary mechanisms targeting different aspects of cancer cell growth and survival.